期刊
TRENDS IN ENDOCRINOLOGY AND METABOLISM
卷 26, 期 1, 页码 22-29出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2014.10.002
关键词
beta Klotho; brown adipose tissue; hypothalamus; sympathetic nervous system; arginine vasopressin; corticotropin-releasing factor
资金
- National Institutes of Health [R01DK067158]
- Robert A. Welch Foundation [I-1558, I-1275]
- Howard Hughes Medical Institute
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067158] Funding Source: NIH RePORTER
Fibroblast growth factors (FGFs) 15/19 and 21 belong to a subfamily of FGFs that function as hormones. Produced in response to specific nutritional cues, they act on overlapping sets of cell surface receptors composed of classic FGF receptors in complex with beta Klotho, and regulate metabolism and related processes during periods of fluctuating energy availability. Pharmacologically, both FGF15/19 and FGF21 cause weight loss and improve both insulin-sensitivity and lipid parameters in rodent and primate models of metabolic disease. Recently, FGF21 was shown to have similar effects in obese patients with type 2 diabetes. We discuss here emerging concepts in FGF15/19 and FGF21 tissue-specific actions and critically assess their putative role as candidate targets for treating metabolic disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据